Status:
UNKNOWN
Trial of Modafinil for Methamphetamine Dependence
Lead Sponsor:
The University of New South Wales
Collaborating Sponsors:
Australian Government Department of Health and Ageing
Kirketon Road Centre, Sydney Hospital
Conditions:
Amphetamine Dependence
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study aims to evaluate the safety and efficacy of modafinil (200 mg/day) over 10 weeks plus a tailored cognitive behavioural therapy program in the treatment of methamphetamine dependence.
Detailed Description
Modafinil is a novel wake promoting agent approved in Australia for the treatment of narcolepsy. Preliminary studies have suggested that modafinil may have value in the treatment of psychostimulant de...
Eligibility Criteria
Inclusion
- Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) amphetamine dependence diagnosis
- Amphetamine positive urine sample at intake
- Regular current amphetamine use (2-3 days per week)
- Aged 18 years or older
Exclusion
- Pregnant or nursing females
- Hazardous concurrent uncontrolled physical or mental illness
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2007
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT00123370
Start Date
July 1 2006
End Date
September 1 2007
Last Update
May 1 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Alcohol and Drug Services, St Vincent's Hospital
Darlinghurst, New South Wales, Australia, 2010
2
Kirketon Road Centre
Darlinghurst, New South Wales, Australia, 2010